SF Healthcare Week: Astellas Pharma CEO Naoki Okamura describes the type of assets the company looks for externally, and covers key internal pipeline assets
- Jan 14
- 1 min read
He talks about KRAS degraders, claudin 18.2, AAV gene therapy, and more. Plus, how Astellas thinks about the coming patent expiry of Xtandi.















.png)

